Bone Health Technologies (BHT) is redefining the landscape of treatments available for low bone mass in postmenopausal women. At the prestigious Endo 2023, BHT showcased the groundbreaking Osteoboost. Selected as a “late-breaking abstract,” the presented data asserts the efficacy of Osteoboost in reducing the decline of bone strength and density.
The double-blinded, sham-controlled study included 126 postmenopausal women with low bone mass, who were not taking bone-active medications. Through Biomechanical Computed Tomography, the study observed that the subjects using Osteoboost displayed an 82% reduction in the rate of bone strength loss. Moreover, there was an 85% reduction in loss of bone density.
Laura Bilek, Ph.D., the principal investigator, highlighted the importance of novel technology in mitigating bone loss post-menopause. Additionally, Laura Yecies, CEO of Bone Health Technologies, emphasized the significance of a non-pharmacological intervention. Osteoboost, a wearable device, employs targeted vibration to the lumbar spine and hips.
The study paves the way for empowering postmenopausal women to maintain their bone health, keeping them active and independent.v
Author
-
Similar Posts
Health-Tech MediBuddy to be the Health Partner for India’s tour of Sri Lanka!
Health-Tech VOBBLE Introduces Innovative, Multi-Sensory Audio Experiences for young kids: A Screen-Free Revolution for Parents!
Health-Tech Kaia Health Introduces First Comprehensive Digital Pain Management Platform in Spanish, Improving Access to Spanish Speakers in the U.S.
